IFN-γ Signaling Sensitizes Melanoma Cells to BH3 Mimetics

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Immunotherapy targeting PD-1 and CTLA-4 offers durable responses in some melanoma patients.
• A significant proportion of patients do not respond to immune checkpoint inhibitors, and up to 60% develop resistance.
• Identifying vulnerabilities in resistant melanoma is crucial for developing alternative treatment strategies.

Purpose of the Study:

• To investigate a vulnerability in melanoma cells that have progressed on PD-1 inhibitor therapy.
• To explore the role of immune cell activity and cytokine signaling in melanoma cell apoptosis.
• To evaluate the potential of BH3 mimetic drugs in combination therapies for resistant melanoma.

Main Methods:

• Establishment and characterization of short-term melanoma cell lines (PD1 PROG) from progressed metastases.
• Analysis of apoptotic regulators MCL-1, NOXA, and BAK in response to IFN-γ.
• Assessment of sensitization of PD1 PROG cells to apoptosis using BH3 mimetic drugs in combination with IFN-γ or autologous immune cells.

Main Results:

• Interferon-gamma (IFN-γ) primes melanoma cells for apoptosis by modulating MCL-1, NOXA, and BAK.
• PD1 PROG melanoma cells exhibit increased sensitivity to apoptosis upon priming with IFN-γ.
• Combination therapy with BH3 mimetics and IFN-γ or immune cell activation effectively induced apoptosis in resistant melanoma cells.

Conclusions:

• Immune cell activity, particularly IFN-γ, creates a vulnerability in melanoma cells resistant to PD-1 inhibitors.
• Modulating apoptotic pathways with BH3 mimetic drugs can re-sensitize resistant melanoma cells to immune-mediated killing.
• These findings support the development of novel combination therapies for melanoma patients who do not respond or progress on current immunotherapies.